Drugs / BCMA CAR-NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05652530 | Nov 2022 → Sep 2023 | plasma cell myeloma | Shenzhen Pregene Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA CAR-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05652530 ↗ |
| Modality | Cell therapy | “This product is allogeneic NK cells which are cryopreserved after in vitro CAR genetic modification and scale-up manufacturing.” NCT05652530 ↗ |